#United States #Cambridge #CREATE Medicines #Allan L. Shaw #biopharma leadership

CREATE Medicines Strengthens Executive Team with Allan Shaw

CREATE Medicines, a pioneering clinical-stage biotechnology firm specializing in RNA-based in vivo multi-immune programming, has recently appointed Allan L. Shaw as its Chief Financial Officer (CFO) and Chief Business Officer (CBO). This strategic move is expected to propel the company into its next growth phase, capitalizing on Shaw's extensive experience in the biopharmaceutical industry.

With over two decades of leadership experience, Shaw has a robust track record in guiding biopharmaceutical organizations through critical growth phases. Throughout his career, he has held senior roles at multiple biopharma companies and has been instrumental in financing, strategic planning, and corporate development activities. His previous tenure as CFO at five publicly-traded companies—including industry leaders like Serono S.A. and Syndax Pharmaceuticals—has provided him with a wealth of knowledge that will prove invaluable to CREATE Medicines.

Shaw's impressive ability to lead companies through challenges is highlighted by his successful facilitation of more than $4 billion in public and private financing arrangements, including several initial public offerings (IPOs). His designation as a board member for seven public company boards further underscores his credibility in the industry. As CREATE Medicines gears up for its next phase of growth, Shaw's expertise will be critical in overseeing the financial strategies and capital formation necessary for expansion.

Daniel Getts, Ph.D., Co-Founder, and CEO of CREATE Medicines expressed his enthusiasm for Shaw's appointment, stating that it represents a pivotal moment for the company. He added, "Allan's unique blend of strategic insight, operational leadership, and transactional expertise will be fundamental as we push forward with our mission to transform cancer treatment and address other immune-related diseases."

Mr. Shaw will primarily focus on enhancing the company's financial foundations and corporate infrastructure while also fortifying relations with investors and strategic partners. His appointment aligns with CREATE Medicines’ recent advancements, such as broadening its pipeline to incorporate T cells and Natural Killer (NK) cells, in addition to myeloid programming.

Shaw expressed his excitement for joining CREATE Medicines during such a transformative time, highlighting the potential impact of the company's programmable immunotherapy platform on the future of disease treatment. He mentioned his eagerness to collaborate closely with Getts and the leadership team to accelerate the development of the company's distinctive in vivo pipeline, bolster its financial capacity, and fully explore the promise of its breakthrough technology.

As CREATE Medicines assembles a leadership team steeped in expertise and experience, it confirms its commitment to advancing innovative therapies and fulfilling its vision of delivering scalable, repeat-dose, off-the-shelf immunotherapies with significant clinical impacts. The future looks bright for CREATE Medicines as it continues its journey toward transforming patient outcomes in the realm of cancer and immune diseases.

About CREATE Medicines

Formerly known as Myeloid Therapeutics, CREATE Medicines is at the forefront of clinical-stage biotech, innovating in vivo multi-immune programming. The company's proprietary mRNA-LNP platform specifically engineers immune cells within the body, leading to scalable, repeat-dose, off-the-shelf immunotherapy solutions. Supported by validated human data and next-generation RNA technology, CREATE is constantly advancing therapies aimed at improving outcomes for cancer patients and those suffering from autoimmune diseases. For further details, please visit createmedicines.com. Follow their journey on LinkedIn and X.